Outcome of Board meeting held on October 23, 2026

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com October 23, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited. (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) Dear Sir/Madam, Sub: Outcome of Board meeting Pursuant to Regulations 30 and 33 and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and in furtherance to our letter dated September 22, 2026, we wish to inform you that the Board of Directors of the Company, at their meeting held today, i.e. October 23, 2026, inter alia considered and approved the following: 1. Unaudited Financial Results for the quarter and half-year ended September 30, 2026 a. Press Release on Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2026; b. Unaudited Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026, prepared in compliance with International Financial Reporting Standards (IFRS) as issued by International Accounting Standards Board (IASB); c. Unaudited Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026, as per Indian Accounting Standards (Ind AS); d. Unaudited Standalone Financial Results of the Company for the quarter and half-year ended September 30, 2026, as per Indian Accounting Standards (Ind AS); and e. Limited Review Reports of the Statutory Auditors on the aforesaid Unaudited Standalone and Consolidated Financial Results as mentioned above. 2. Appointment of Mr. Akhil Ravi as a Senior Management Personnel Pursuant to the recommendation of the Nomination, Governance and Compensation Committee and Audit Committee, the Board of Directors of the Company, at their meeting held today, approved the appointment of Mr. Akhil Ravi as Head API and Services and Senior Management Personnel of the Company, and his induction as a Member of the Management Council of the Company, effective November 13, 2026. Mr. Akhil Ravi will continue to be responsible for the operations of Aurigene Pharmaceutical Services Ltd. a wholly owned subsidiary of the Company. Mr. Akhil Ravi is a related party to the Company, being the son- in-law of Mr. G V Prasad, Co-Chairman and Managing Director. The revised list of Senior Management Personnel is attached as Annexure. The disclosures required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are attached as Annexures. The Board Meeting commenced at 3:00 p.m. IST and concluded at 4:38 p.m. IST. This is for your information and records. Thanking you. Yours faithfully, For Dr. Reddy’s Laboratories Limited K Randhir Singh Company Secretary, Compliance Officer & Head-CSR Encl: as above Dr.Red�d;y•' s PreRsesl ease DRR.E DDYL'ASB ORATOLRTIDE.S INVESRTEOLRA TIONS MEDIRAE LATIONS 8-2-R3o3aN7do,3 . B, a njHairlal s, Hyder-a5b0a0d0T 3e4l.a nIgnadniaa,. AISHWASRIYTAH ARAM SANTOVSYHA S asihwaryasdrjrdtheda.yoracsmm @santoshvyas@drreddys.com DrR.e ddQy2'& s H1FFYi2n7a nRceisaull ts HyderaIbnaddOi,ca t,o 2b3e2,r0 2D6r:R. e ddLya'bso raLtt.o(d rBiS5eE0s:0 12N4S ED:R REDDY NYSER:D YN SEIDFRSCR:E D)tD oYdaanyn ouintccsoe nds olfiindaantrceeidsa ufollr tt hqseu aratnedr simxo ntehnsd eSde pte3m0b2,e0 r2 T6h.ei nformamteinotni ionnt ehdir se leiasbs aes oend consolfiindaantscetidaa tle umnednIettnrse rnaFtiinoannRacelip aolrS ttianngd( aIrFdRsS ). Particulars Q2FY27 H1FY27 Revenues =t8 6,7M0n8 =t1 67,413 Mn [oDwn1:. 5Y%o UYp;7 .4Q%o Q] [Dow3n.:5Y %o Y] GroMsasr gin 52.1% 49.4% [2QFY2564:. 7Q%1F;Y 2:47 6.5%[]H 1FY26: 55.8%] EBITDA =t1 7,8M2n8 =t2 7,9M1n5 [20.o6fR% e venues] [16.o7fR%e venues] ProbfeiftoT raex =t1 2,2M7n7 =t1 7,8M0n3 [14.o2fR% e venues] [10.o6fR% e venues] ProafftietTr a x =t9 ,2M5n0 =t1 3,6M8n5 attribtuoEt qaubHilotely d e[r1s0 .o7fR%e venues] [8.o2Rf%e venues] NotQe1:F Yr2e7s wuelrtiesm pacdtuteeoad f 2,M3n9p 7r ovitsoiwoainrn dvse natnaodsr syo ccioasrtteesld at tose edm aglutide's actpihvaer macienugtriec(da'ilse enmta AgPlr!ue tliaidtmeep da ct'). Commentointn hgre e suClot-sC,h ai&rM mDaG,n PV r assaadi" dW:ce o ntitnoiu mepdrt ohvoeev erall healotfoh ub ru sindeeslsi,vd eoruibnlgeb -adsbieug siitgn reoswsat nhEd B ITmDaAr goifon vs e2r0 % duritnhqgeu arWteer re.m afionc uosnse tdr engtohuceron rbieun sgi neenshsaenspc,ri ondgu catnidv ity, invesitnsi tnrga gtreogwiptclh a tftoodr emlsic voenrs ipsetrefnotr wmhainclcreee ,a ltoinngg- vtaelrume drivers." Particulars I Q2FY27 Q2FY26 I I YoY Q1FY27 Gr% Gr% ' ($) (f) ($) (f) ($) (f) Revenues 905 86,70981 9 88,051( 2) 842 80,705 7 CosoftR evenues 433 41,5044 16 39,9114 450 431,65 (4) GroPs11so fit 4o/2 45,204s oi48 .,14(60), 392 l't7,S420'0 %o Rfe venues ' 52.1% 54.7% 46.5% SellGiennge&,rA adlm inistrati2v9e3 E2x8p,e0n725s7 e6s 26,4366 301 28,820( 3) %o Rfe venues 32.4% 30.0% 35.7% Rese&aD recvhe loEpxmpeennts es 55 5,2356 5 6,202( 16) 60 5,766 (9) %o Rfe venues 6.0% 7.0% 7.1% ImpairomfNeo nnt- CuArsrseenntetst , 1 123 7 662 (81) 0 15 720 Oth(elrn come)n/eExtpense,( 10)(912)(28)(2,673()66) (9) (845) 8 Re,_sultON'penJo'mAa cttiiuvgi ties 1!3'2 !l2-,683 1i83 1715,1(328) 39 Bi7842' 35 Fina(nIcnec ome)n/eEtx pense,3 329 (8) (774)(143)(18)(1,73(41)1 9) ShaorfPe r oofifEt q uIintyv esnteoettfe a sx,1 77 (1) (63)(222)(0) (8) (1,063) P11otltbelfommFme'i!T ax -�-= "' ' -� ----C33l5 8 5,5lr61 22 %o Rfe venues I 14.2I% • I �;0 •.%1'811 68.% IncoTmaEexx pense/(Benefit3)3 3,1434 3 4,082( 23) 12 1,1781 67 """'··"""'"""" · R,rfoorflt th P.ee r.iod "'�·�f 63) ' 4t5 4,34:81 10 %o Rfe ve.n, 1�es W.'5% I M.2% -45.% AttribtuoEt qaubhilotyel doefPr asr Ceon.t9 7 9,2501 50 14,372( 36) 46 4,435109 ' I I %0 f,Revenues I :J.0.7% 1'6:3 I% I I S.:S% AttribtuoNt oanb-lceo nitnrtoelrleisn(tg1s ) (116)(1) (104)13 (1) (87) 35 •JY�J•E.ar�gse�_:,r·, _ �., ®IA' �'111.I � :a• f36)Q ,06 s.a-- ,,i1 09 Q2FY27 Q2FY26 Q1FY27 Particulars (f) (f) (f) ($) ($) ($) Probfietfo rIen coTmaex 128 12,27179 1 18,35508 5,526 Inte(rIensct/o E mxep)enneste*, 2 159 (6) (552)(9) (825) Depreciation 36 3,4893 2 3,0913 5 3,380 Amortization 19 1,7802 0 1,9602 1 1,992 Impairment 1 123 7 662 0.2 15 186 11,00-8il 4J5 23,5'1,110 5 J..0,088 % oRfe venues 1 20.6% I 26.7% '---- *IncilnucdfoermsoeI m n vestment